WuXi XDC, a global CDMO providing end-to-end bioconjugates services, and LegoChem Biosciences (LCB), signed a Memorandum of Understanding (MOU) for a partnership in development and manufacturing of antibody-drug conjugates (ADCs).
 
LCB will have access to XDC’s integrated services in mAb, linker, payload, analytical and formulation development as well as ADC drug substance and drug product development and manufacturing. XDC will provide a full range of development and manufacturing services in one centralized region, which is within 2 hours’ driving distance.
 
“We’re excited to collaborate with WuXi XDC,” said Yong-Zu Kim, CEO and president, LCB. “This partnership will allow us to leverage XDC’s world-class expertise in both innovative conjugation technologies and the comprehensive capabilities for the ADC development and manufacturing. We’re looking forward to making more ADC products accessible to the patients.”
 
Jimmy Li, CEO, WuXi XDC, said, “We’re glad to partner with LegoChem Biosciences to proceed its leading ADC products into clinical development, eventually to the commercialization. With more ADC programs now advancing towards clinical trials and commercial production, we have witnessed increasing outsourced demand for ADCs in recent years. As one of a few CDMO companies who have the end-to-end capability and entire supply chain, we’re committed to providing innovative technical solutions, reliable and sustainable manufacturing supply chain for global partners to benefit patients worldwide.”